Blis Gets Key ‘Letter of No Objection’ From US FDA
For immediate release
January 29, 2016
Blis Technologies Gets Key ‘Letter of No Objection’ From US Food and Drug Administration for Ingredient BLIS K12
NZX-listed Blis Technologies Limited announced today that one of the company’s key products, the ingredient BLIS K12, had the issuance of a US Food and Drug Administration ‘Letter of No Objection’.
Blis Technologies board chairman Peter Fennessy said the Letter of No Objection, more commonly known as GRAS or ‘Generally Recognized As Safe’, is another step on the strategic pathway to opening markets through regulatory approval.
“It adds a new level of credibility for BLIS K12 and puts the conversations with larger consumer food and beverage companies in the US on a stronger footing.
“Many of those companies are, quite rightly, risk averse. Therefore, having GRAS status offers an additional level of confidence. GRAS status makes it clearer where BLIS K12 fits within the category.”
Through the GRAS program, companies may submit their determination, supported by research and expert review, that a specific ingredient is Generally Recognized As Safe. The Letter of No Objection means that the FDA has reviewed the data and has no questions regarding the notice submitted.
Jeremy Moore, Managing Director of Blis Technologies’ US distributor, Stratum Nutrition, said very few ingredients in this space go to this level so it is a definite feather in the cap for Blis.